



**Externally-Led Patient Focused Drug Development Meeting for
Autoimmune Pulmonary Alveolar Proteinosis (aPAP)**

Wednesday, May 7, 2025

Virtual Meeting Agenda

- 12:30 PM** **Opening remarks**
Pamela Gavin, CEO, NORD
- 12:40 PM** **Clinical Overview of Autoimmune Pulmonary Alveolar Proteinosis**
Dr. Bruce Trapnell, Board Chairman & Scientific Director, PAP Foundation
- 12:55 PM** **Welcome, an Agency Perspective on Patient Focused Drug Development**
Dr. Elisabeth Boulos, Division of Pulmonary, Allergy, and Critical Care, U.S. Food and Drug Administration
- 1:05 PM** **Introduction and Meeting Overview**
Alli Ward, Director of Membership, NORD
Dr. Bruce Trapnell, Board Chairman & Scientific Director, PAP Foundation
- 1:20 PM** **Demographic Polling**
Alli Ward, Director of Membership, NORD
- 1:30 PM** **Panel Discussion: Living with Autoimmune Pulmonary Alveolar Proteinosis**
Karli S., Patient
Mercedes C., Caregiver
Steve P., Patient
Kelsea A., Patient
- 2:05 PM** **Polling Questions and Facilitated Audience Discussion**
Alli Ward, Director of Membership, NORD
- 2:50 PM** **Break**
- 3:00 PM** **Panel Discussion: Current Management & Future Treatments**
Gigi R., Patient
John K., Patient
Shona M., Patient
Tracey D., Patient
Emily S., Patient



3:35 – 4:20pm

Polling Questions and Facilitate Audience Discussion

Alli Ward, Director of Membership, NORD

4:20 PM

Closing Remarks & Next Steps

Chris Hameetman, President and CEO, PAP Foundation

Support for this meeting was provided by Savara Pharmaceuticals.